arrow
S

Shafeeq Ladha

arizona state university-tempe
H指数:31
被引数:4,388

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of nusinersen in adult patients with Spinal Muscular Atrophy

一项关于nusinersen在成人脊髓性肌萎缩症患者中安全性、耐受性和有效性的前瞻性、多中心、观察性研究。

2025-10-240
PRE
Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis

多中心扩展性访问方案:通过向肌萎缩侧索硬化症患者提供海藻糖进行研究

2025-08-260
OAAI
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial

avalglucosidase alfa在COMET试验中治疗晚期发作型庞贝病145周后的疗效与安全性

2025-08-160
OA
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis

肌萎缩侧索硬化症托尔瑟森临床试验中的严重神经不良事件

2025-02-274
OAAI
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis, A Randomized Clinical Trial

Zilucoplan治疗肌萎缩侧索硬化症的疗效与安全性:一项随机临床试验

2025-02-173
OA
NEO1/NEO-EXT studies: Long-term muscle quantitative magnetic resonance imaging and functional efficacy in adults with lateonset Pompe disease (LOPD) on avalglucosidase alfa treatment
2024-02-010
PRE
Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial
2023-02-011
PRE
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
2022-08-0224
OAAI
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
2022-05-1651
OAAI
The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
2022-02-011
PRE
NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD)
2021-02-011
PREAI
Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients
2021-02-012
PREAI
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
2020-09-03345
OAAI
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
2020-07-09372
OAAI
NEO1 and NEO-EXT studies: Long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients
2020-02-015
PREAI